Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

V 503

Drug Profile

V 503

Alternative Names: 9-valent HPV vaccine - Merck and Co; 9-valent human papillomavirus vaccine - Merck and Co; 9vHPV vaccine - Merck; GARDASIL; GARDASIL9; Human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52, 58) L1 virus-like particle vaccine - Merck; Human Papillomavirus 9-valent vaccine, Recombinant; Human papillomavirus vaccine recombinant 9-valent - Merck; Human papillomavirus vaccine recombinant nonavalent - Merck; Human papillomavirus vaccine-Merck-9 valent; Multivalent human papillomavirus (HPV) L1 virus-like particle (VLP) vaccine - Merck; Nonavalent HPV VLP Vaccine; Recombinant HPV 9-valent Vaccine; Recombinant HPV Nonavalent Vaccine; Recombinant Human Papillomavirus 9-valent Vaccine; SILGARD9; V-503

Latest Information Update: 02 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Developer Banyu; Merck & Co; Takeda
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Papillomavirus vaccines; Synthetic vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Anal cancer; Cervical cancer; Condylomata acuminata; Head and neck cancer; Human papillomavirus infections; Oropharyngeal cancer; Vulvovaginal cancer
  • Phase III COVID 2019 infections; Dengue

Most Recent Events

  • 06 Apr 2024 Merck Sharp & Dohme completes a phase III V503-066 trial for Human papillomavirus infections (In children, In adolescents, Prevention) in Japan (IM) (NCT04772534)
  • 13 Mar 2024 Merck AG plans a phase I trial for Human Papillomavirus infections in males (In adolescents, In adults, Prevention) (IM) in the fourth quarter of 2024
  • 13 Mar 2024 Merck AG plans a phase I trial for Human Papillomavirus infections in females (In adolescents, In adults, Prevention) (IM) in the fourth quarter of 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top